Cayman Chemical Company Incorporated

Myometrics LLC

Bradlee David Germain

Stephen Douglas Barrett

Adam Uzieblo

James Bernard Kramer

Joseph Michael Colombo

Gregory William Endres

Andriy Kornilov

Fred Lawrence Ciske

Kirk M Maxey

Thomas Allen Owen

James Paul O'Malley

Andriy Komilov

James Paul O'malley

Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L, L, L, R, R, R, R, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

The present invention relates to processes and intermediates for preparing compounds of formula (IA), wherein R, R, R, R, and Lare as defined herein. Compounds of formula (IA) have been found useful as EPreceptor agonists useful in the treatment of glaucoma, osteoporosis, neuropathic pain, and related disorders. 

Methods of synthesizing a difluorolactam analog

The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

Methods, systems, and compositions for promoting bone growth

Difluorolactam compounds as EPreceptor-selective agonists for use in the treatment of EP-mediated diseases and conditions

Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L, L, L, R, R, R, R, and s are as defined in the specification.

[object Object]

Disclosed herein are compounds of formula (I) wherein L, L, L, L, R, R, R, R, and s are as defined in the specification. Compounds of formula (I) are EPagonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

Disclosed herein are compounds of formula (I) wherein L, L, L, R, R, R, and Rare as defined in the specification. Compounds of formula (I) are EPagonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

Disclosed herein are compositions and methods of treating osteoporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L, L, L, R, R, R, R, and s are as defined in the specification.

Growing community of inventors

Ann Arbor, MI, United States of America

Bradlee David Germain